Multiple Sclerosis Drugs Market: By Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Drug Class (Disease Modifying Drugs (DMDs), Steroids, Others), and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Multiple Sclerosis Drugs Market size was valued at USD 25.71 billion in 2023 and is poised to grow at a CAGR of 4.0% over the forecast period 2024-30.  Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, particularly the brain and spinal cord. There is currently no cure for MS, but several disease-modifying therapies (DMTs) and symptomatic treatments are available to manage the condition and improve the quality of life for individuals with Multiple Sclerosis. Physically, individuals with Multiple Sclerosis often grapple with debilitating fatigue, which can affect daily activities and overall quality of life. Mobility issues, such as difficulties with walking, balance, coordination, and muscle weakness, are common. The Multiple Sclerosis drug market is experiencing growth driven by several factors. One of the key drivers is the unmet need for drugs to treat Multiple Sclerosis (MS). With extensive research and development (R&D) pipelines, pharmaceutical companies are actively working on new treatments for the disease. MS is a prevalent condition, with approximately 2.3 million people affected globally.

Notably, a significant portion of Multiple Sclerosis cases remains undiagnosed in certain parts of the world due to a lack of healthcare infrastructure and limited awareness about the disease. Advancements in biomedical science are creating profitable opportunities for Multiple Sclerosis drug manufacturers in the near future. However, the market also faces challenges, including the patent expiry of key drugs, which can impact market dynamics. Additionally, regulatory requirements and procedures have been strengthening, presenting obstacles to steady market growth. The global Multiple Sclerosis drugs market is notably influenced by the increasing number of patients with secondary progressive relapsing-remitting multiple sclerosis. Efforts by organizations like the National Multiple Sclerosis Society and the Multiple Sclerosis Association of America (MSAA) have played a significant role in raising awareness about the disease and its associated symptoms, contributing to better identification and diagnosis. Overall, the Multiple Sclerosis drug market exhibits both promising growth prospects and challenges, shaped by factors such as the disease's prevalence, evolving R&D efforts, patent issues, and regulatory considerations.

Global Multiple Sclerosis Drugs Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

4%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Multiple Sclerosis Drugs Market Dynamics

The global multiple sclerosis drugs market is majorly influenced by increased number of patients from secondary progressive relapsing-remitting multiple sclerosis. The awareness in identifying multiple sclerosis disease conditions increased because of organizations such as National MS society and Multiple Sclerosis Association of America (MSAA) are actively involved in educating the people regarding associated symptoms and increasing the awareness.

Global Multiple Sclerosis Drugs Market Segmentation

By Administration
  • Oral
  • Parenteral
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
By Drug Class
  • Disease Modifying Drugs (DMDs)
  • Steroids
  • Others

Frequently Asked Questions

Multiple Sclerosis Drugs Market size was valued at USD 25.71 billion in 2023 and is poised to grow at a CAGR of 4.0% over the forecast period 2024-30.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1.Executive Summary
2.Global Multiple Sclerosis Drugs Market Introduction 
2.1.Global Multiple Sclerosis Drugs Market  - Taxonomy
2.2.Global Multiple Sclerosis Drugs Market  - Definitions
2.2.1.Administration
2.2.2.Distribution Channel
2.2.3.Drug Class
2.2.4.Region
3.Global Multiple Sclerosis Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Multiple Sclerosis Drugs Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Multiple Sclerosis Drugs Market  By Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Oral
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Parenteral
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6.Global Multiple Sclerosis Drugs Market  By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Hospital Pharmacy
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Retail Pharmacy
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Online Pharmacy
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7.Global Multiple Sclerosis Drugs Market  By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Disease Modifying Drugs (DMDs)
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Steroids
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Others
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Multiple Sclerosis Drugs Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Multiple Sclerosis Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Oral
9.1.2.Parenteral
9.2.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Hospital Pharmacy
9.2.2.Retail Pharmacy
9.2.3.Online Pharmacy
9.3.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Disease Modifying Drugs (DMDs)
9.3.2.Steroids
9.3.3.Others
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Multiple Sclerosis Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Administration Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Oral
10.1.2.Parenteral
10.2.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Hospital Pharmacy
10.2.2.Retail Pharmacy
10.2.3.Online Pharmacy
10.3.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Disease Modifying Drugs (DMDs)
10.3.2.Steroids
10.3.3.Others
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Multiple Sclerosis Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Administration Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Oral
11.1.2.Parenteral
11.2.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Hospital Pharmacy
11.2.2.Retail Pharmacy
11.2.3.Online Pharmacy
11.3.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Disease Modifying Drugs (DMDs)
11.3.2.Steroids
11.3.3.Others
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Multiple Sclerosis Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Administration Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Oral
12.1.2.Parenteral
12.2.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Hospital Pharmacy
12.2.2.Retail Pharmacy
12.2.3.Online Pharmacy
12.3.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Disease Modifying Drugs (DMDs)
12.3.2.Steroids
12.3.3.Others
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Multiple Sclerosis Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Administration Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Oral
13.1.2.Parenteral
13.2.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Hospital Pharmacy
13.2.2.Retail Pharmacy
13.2.3.Online Pharmacy
13.3.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Disease Modifying Drugs (DMDs)
13.3.2.Steroids
13.3.3.Others
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Novartis AG
14.2.2.Teva Pharmaceutical industries Ltd.
14.2.3.Biogen, Inc.
14.2.4.Merck & Co., Inc.
14.2.5.Sanofi
14.2.6.Acorda Therapeuitics
14.2.7.Pfizer Inc.
14.2.8.Bayer AG
14.2.9.Medtronic plc
15. Research Methodology 
16. Appendix and Abbreviations 
  • Novartis AG
  • Teva Pharmaceutical industries Ltd.
  • Biogen, Inc.
  • Merck & Co., Inc.
  • Sanofi
  • Acorda Therapeuitics
  • Pfizer Inc.
  • Bayer AG
  • Medtronic plc

Adjacent Markets